SEC Form 4 · accession 0001193125-26-363567
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John M Leonard
Officer — President and CEO · Director
Period of report
Aug 20, 2026
Accepted (ET)
Aug 24, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 20, 2026 | S | 19,890 | $12.60 | D | 1,149,849 | D | |
| Common Stock | Aug 21, 2026 | S | 2,785 | $13.00 | D | 1,147,064 | D | |
| Common StockF3 | holding | — | — | — | 58,415 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.
- F3Shares held by the John M. Leonard 2015 Irrevocable Trust.